Trial Profile
Phase III trial of pramlintide + metreleptin combination therapy in patients with obesity.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Aug 2011
Price :
$35
*
At a glance
- Drugs Pramlintide-metreleptin (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Sponsors Amylin Pharmaceuticals; Takeda
- 04 Aug 2011 Status changed from planning to discontinued.
- 24 Feb 2010 New trial record